当前位置: X-MOL 学术Psychol. Sci. Public Interest › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
About the Authors
Psychological Science in the Public Interest ( IF 25.4 ) Pub Date : 2018-04-03 , DOI: 10.1177/1529100618766877


Victor J. Dzau is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine. In addition, he serves as Vice Chair of the National Research Council. He is an internationally acclaimed leader and scientist whose work has improved health care in the United States and globally. Since arriving at the National Academies, Dzau has led important initiatives such as the Commission on a Global Health Risk Framework for the Future, the Human Gene Editing Initiative, Vital Directions for Health and Health Care, and the NAM Grand Challenges in Healthy Longevity. His own research laid the foundation for development of a lifesaving class of drugs, ACE inhibitors, used globally to treat high blood pressure and congestive heart failure. He pioneered gene therapy for vascular disease. He is a member of the board of directors of the Singapore Health Services, a former member of the Advisory Committees to the Director of U.S. National Institutes of Health (NIH), chaired NIH’s Cardiovascular Disease Advisory Committee, and is past chair of the Association of Academic Health Centers. Dzau has previously served as Chancellor for Health Affairs and President and CEO of Duke University Health system. He has received numerous awards, including the Max Delbruck Medal from Germany, the Gustav Nylin Medal from the Swedish Royal College of Medicine, the Polzer Prize from the European Academy of Sciences & Arts, the Ellis Island Medal of Honor, and the Distinguished Scientist Award of the American Heart Association.

中文翻译:

关于作者

维克多·J·佐是美国国家医学研究院(NAM)的主席,前身是医学研究所。此外,他还担任国家研究委员会副主席。他是享誉国际的领导人和科学家,他的工作改善了美国和全球的医疗保健。自到达国家研究院以来,Dzau领导了重要的倡议,例如未来全球健康风险框架委员会,人类基因编辑倡议,健康和保健的重要方向以及NAM健康长寿的巨大挑战。他自己的研究为开发可挽救生命的一类药物ACE抑制剂奠定了基础,这种药物在全球范围内用于治疗高血压和充血性心力衰竭。他开创了用于血管疾病的基因疗法。他是新加坡卫生服务局的董事会成员,美国国立卫生研究院(NIH)主任咨询委员会的前任成员,NIH心血管疾病咨询委员会的主席,并且是新加坡卫生学会的前任主席。学术健康中心。Dzau之前曾担任卫生事务大臣以及杜克大学卫生系统总裁兼首席执行官。他获得了无数奖项,包括德国的马克斯·德尔布鲁克奖章,瑞典皇家医学院的古斯塔夫·尼林奖章,欧洲科学与艺术学院的波尔泽奖,埃利斯岛荣誉勋章和杰出科学家奖。美国心脏协会。曾担任NIH心血管疾病咨询委员会主席,并曾担任学术健康中心协会主席。Dzau之前曾担任卫生事务大臣以及杜克大学卫生系统总裁兼首席执行官。他获得了无数奖项,包括德国的马克斯·德尔布鲁克奖章,瑞典皇家医学院的古斯塔夫·尼林奖章,欧洲科学与艺术学院的波尔泽奖,埃利斯岛荣誉勋章和杰出科学家奖。美国心脏协会。曾担任NIH心血管疾病咨询委员会主席,并曾担任学术健康中心协会主席。Dzau之前曾担任卫生事务大臣以及杜克大学卫生系统总裁兼首席执行官。他获得了无数奖项,包括德国的马克斯·德尔布鲁克奖章,瑞典皇家医学院的古斯塔夫·尼林奖章,欧洲科学与艺术学院的波尔泽奖,埃利斯岛荣誉勋章和杰出科学家奖。美国心脏协会。
更新日期:2018-04-03
down
wechat
bug